Pavaki Capital Management LLC

Position in NVO — Novo Nordisk A S

CIK 2143027

Back to NVO Full portfolio

Position in NVO

as of Jun 30, 2026 · filed Aug 7, 2026 Compact

Position Value

$215,730

+$50,355 QoQ

Shares Held

4,500

0.0% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.13%

of 13F equity value

Holder Rank

#1,006

of 1,348 holders

Holding Since

Dec 2025

3 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVO Over Time

Shares Held

Position Value (USD)

Derivatives in NVO

reported options exposure · as of Dec 31, 2025

CallValue

CallShares

PutValue

$508,800

PutShares

10,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

Pavaki Capital Management LLC holds $2,766,232 across 5 Drug Manufacturers - General names. NVO ranks #5 (7.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	SNY	Sanofi	20,000	$853,200
2	BIIB	Biogen Inc.	3,500	$756,210
3	MRK	Merck & Co., Inc.	5,000	$642,500
4	PFE	Pfizer Inc	12,400	$298,592
5	NVO	Novo Nordisk A S This page	4,500	$215,730

All Filings in NVO

Export CSV

4 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$215,730	4,500	0.0%	Shares	Sole	2026-08-07
2026-03-31	$165,375	4,500	0.0%	Shares	Sole	2026-08-07
2025-12-31	$508,800	10,000	—	Put	Sole	2026-08-07
2025-12-31	$228,960	4,500	—	Shares	Sole	2026-08-07
No filing history on record for this holder in this stock.